Genitourinary Cancers Symposium Annual Meeting Coverage

Genitourinary Cancers Symposium

Yellow tablets in a man's hand

Unique Drug Cuts CRPC Mets Risk

SAN FRANCISCO—Darolutamide, a structurally unique androgen receptor antagonist, prolongs metastasis-free survival (MFS) and decreases the risk of pain progression in men with nonmetastatic castration-resistant prostate cancer (nmCRPC), without adversely affecting quality of life, according to study findings presented at the 2019 Genitourinary Cancers Symposium and published concurrently in The New England Journal of Medicine. “This…

Next post in Genitourinary Cancers Symposium